trial
as of 2026-07-01RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
NCTId NCT01490086
at a glance
Phase 2 · Completed
Enrollment 234 (actual)
Sponsored by Reviva Pharmaceuticals
Primary completion 2013-03
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
234 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-12
Primary completion
2013-03
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Reviva PharmaceuticalsLead Sponsor
Investigators
1
M CantillonStudy Director
Sites
15 total
Philadelphia, United StatesBangalore, IndiaChennai, IndiaGuntur, IndiaJaipur, IndiaKanpur, IndiaLucknow, IndiaMangalore, IndiaJohor Bahru, MalaysiaKuala Lumpur, MalaysiaTanjung Rambutan, MalaysiaChisinau, Moldova
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
234
Phase
PHASE2
Primary Completion Date
2013-03
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
investigator
person